Join the Keytruda group to help and get support from people like you.
Keytruda News (Page 2)
FDA Approves KEYTRUDA + Chemo for Primary Advanced, Recurrent Endometrial Carcinoma
FRIDAY, June 21, 2024 – The U.S. Food and Drug Administration has approved Keytruda (pembrolizumab) plus chemotherapy as treatment for adult patients with primary advanced or recurrent endometrial...
FDA Approves Merck’s Keytruda (pembrolizumab) Plus Carboplatin and Paclitaxel as Treatment for Adult Patients With Primary Advanced or Recurrent Endometrial Carcinoma
RAHWAY, N.J.--(BUSINESS WIRE) June 17, 2024 – Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has approved...
Alternative Pembrolizumab Administration Yields Environmental Advantages
THURSDAY, June 13, 2024 – Alternative pembrolizumab administration strategies may have environmental advantages, such as less carbon dioxide emission, according to a study published in the June...
FDA Approves Merck’s Keytruda (pembrolizumab) Plus Chemoradiotherapy as Treatment for Patients With FIGO 2014 Stage III-IVA Cervical Cancer
Keytruda is the first and only anti-PD-1 therapy approved in combination with chemoradiotherapy for these patients Approval marks third FDA-approved indication for Keytruda in cervical cancer and...
Padcev (enfortumab vedotin-ejfv) with Keytruda (pembrolizumab) Approved by FDA as the First and Only ADC Plus PD-1 to Treat Advanced Bladder Cancer
Padcev plus pembrolizumab approved based on groundbreaking EV-302 trial Confirmatory trial found Padcev plus pembrolizumab nearly doubled median overall survival compared to standard of care...
FDA Approves Merck’s Keytruda (pembrolizumab) Plus Gemcitabine and Cisplatin as Treatment for Patients With Locally Advanced Unresectable or Metastatic Biliary Tract Cancer
RAHWAY, N.J.--(BUSINESS WIRE) November 1, 2023 – Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has...
FDA Approves Keytruda (pembrolizumab) for Treatment of Patients With Resectable NSCLC in Combination With Chemotherapy as Neoadjuvant Treatment, Then Single Agent as Adjuvant Treatment After Surgery
RAHWAY, N.J.--(BUSINESS WIRE) October 16, 2023 – Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has...
FDA Approves Merck’s Keytruda (pembrolizumab) in Combination With Padcev (enfortumab vedotin-ejfv) for First-Line Treatment of Certain Patients With Locally Advanced or Metastatic Urothelial Cancer
RAHWAY, N.J.--(BUSINESS WIRE) April 3, 2023 – Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has approved...
FDA Approves Keytruda (pembrolizumab) as Adjuvant Treatment Following Surgical Resection and Platinum-Based Chemotherapy for Patients With Stage IB (T2a ≥4 Centimeters), II, or IIIA Non-Small Cell Lung Cancer (NSCLC)
Approval based on KEYNOTE-091 trial, which demonstrated a clinically meaningful improvement in disease-free survival with KEYTRUDA in these patients following surgical resection and platinum-based...
FDA Approves Merck’s Keytruda (pembrolizumab) for Patients With MSI‑H/dMMR Advanced Endometrial Carcinoma, Who Have Disease Progression Following Prior Systemic Therapy in Any Setting and Are Not Candidates for Curative Surgery or Radiation
KENILWORTH, N.J.--(BUSINESS WIRE) March 21, 2022 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved...
FDA Approves Merck’s Keytruda (pembrolizumab) Plus Chemotherapy, With or Without Bevacizumab, as Treatment for Patients With Persistent, Recurrent or Metastatic Cervical Cancer Whose Tumors Express PD-L1 (CPS ≥1)
KENILWORTH, N.J.--(BUSINESS WIRE) October 13, 2021 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has...
FDA Approves Expanded Indication for Merck’s Keytruda (pembrolizumab) in Locally Advanced Cutaneous Squamous Cell Carcinoma (cSCC)
Keytruda Is Now Approved for the Treatment of Patients With Recurrent or Metastatic or Locally Advanced cSCC That Is Not Curable by Surgery or Radiation KENILWORTH, N.J.--(BUSINESS WIRE) July 6, ...
FDA Approves Keytruda (pembrolizumab) Plus Lenvima (lenvatinib) Combination for Patients With Certain Types of Advanced Endometrial Carcinoma
KENILWORTH & WOODCLIFF, N.J.--(BUSINESS WIRE) July 22, 2021 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Eisai Inc. today announced that the U.S. Food and Drug...
FDA Approves Keytruda (pembrolizumab) for Treatment of Patients With High-Risk Early-Stage Triple-Negative Breast Cancer in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as Single Agent as Adjuvant Treatment After Surgery
KENILWORTH, N.J.--(BUSINESS WIRE) July 27, 2021 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved...
FDA Approves Keytruda (pembrolizumab) Plus Lenvima (lenvatinib) Combination for First-Line Treatment of Adult Patients With Advanced Renal Cell Carcinoma (RCC)
August 11, 2021 Keytruda Plus Lenvima Is Now Approved for Two Types of Cancer, Including Advanced RCC Based on Phase 3 CLEAR/KEYNOTE-581 Trial, Keytruda Plus Lenvima Significantly Reduced Risk of...
Further information
Related condition support groups
Breast Cancer, Colorectal Cancer, Endometrial Cancer, Gastric Cancer, Hepatocellular Carcinoma, Melanoma, Non-Small Cell Lung Cancer, Renal Cell Carcinoma